Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the epithelial lining of the biliary tree. The disease is traditionally divided by anatomic origin into three subtypes: intrahepatic (iCCA, arising from small bile ducts within the liver), perihilar (pCCA, at the hepatic duct confluence), and distal (dCCA, within the extrahepatic bile duct below the cystic duct). Each subtype has distinct surgical considerations, molecular profiles, and prognostic trajectories. This review consolidates current staging, a treatment algorithm by stage and location, and an evidence-based integrative oncology checklist, including the specific evidence for low-dose naltrexone (LDN), alpha-lipoic acid (ALA), ketogenic strategies, and intravenous vitamin C (IVC).

Diagnosis, in brief

Workup generally begins with obstructive jaundice or an incidental liver mass. Contrast-enhanced CT with a multiphase liver protocol and MRI with MRCP are the imaging standards; MRCP is preferred for defining biliary anatomy in perihilar disease. CA 19-9 is a supportive marker but is neither sensitive nor specific and is often spuriously elevated in the setting of biliary obstruction. Tissue confirmation is pursued with EUS-guided fine-needle aspiration for distal lesions, brush cytology with fluorescence in situ hybridization via ERCP for ductal lesions, and percutaneous or image-guided biopsy for intrahepatic mass-forming tumors. Comprehensive genomic profiling (tissue or liquid biopsy) should be obtained early in any patient with advanced disease because approximately half of cholangiocarcinomas carry at least one actionable alteration.

1. One-Page Staging Summary (AJCC 8th Edition)

The 8th edition of the AJCC/UICC staging system (mandatory since January 2018) stages the three anatomic subtypes separately. The framework below is deliberately condensed to fit one clinical page; full definitions remain in the AJCC manual.

Intrahepatic cholangiocarcinoma (iCCA)

Key 8th-edition updates: T1 is now subdivided at 5 cm; periductal invasion no longer defines T4; and nodal disease and T4 were downstaged from stage IV to IIIB. Recovery of at least six lymph nodes is recommended for adequate nodal staging.

Perihilar cholangiocarcinoma (pCCA)

Bismuth–Corlette classification (I–IV) remains the surgical roadmap for perihilar disease, complementing AJCC staging.

Distal cholangiocarcinoma (dCCA)

Only approximately 20% of patients with biliary tract cancer present with resectable disease. Five-year overall survival after curative-intent resection remains around 25–30% for early-stage iCCA, reflecting high recurrence rates even after R0 resection.

2. Treatment Algorithm by Stage and Location

Resectable disease: surgery first

Complete surgical resection with negative margins (R0) remains the only potentially curative therapy and is the backbone of management for resectable disease across all three subtypes. Intrahepatic tumors are addressed by anatomic or non-anatomic hepatectomy with regional lymphadenectomy; perihilar tumors require extended hepatectomy with caudate resection and bile duct reconstruction; distal tumors require pancreaticoduodenectomy. In select patients with unresectable, early-stage perihilar cholangiocarcinoma who meet strict criteria (typically tumors ≤ 3 cm, no intrahepatic or extrahepatic metastases, and acceptable performance status), neoadjuvant chemoradiation followed by orthotopic liver transplantation under the Mayo protocol achieves five-year survival of roughly 65–70% at experienced centers and represents an important alternative to resection for a narrowly selected population.

Adjuvant therapy: capecitabine

Adjuvant oral capecitabine for six months (1,250 mg/m² twice daily on days 1–14 of a 21-day cycle for eight cycles) is the recommended standard of care following macroscopically complete resection. The phase III BILCAP trial (Primrose et al., Lancet Oncology 2019), although the study did not meet its primary endpoint in the intention-to-treat analysis, showed a clinically meaningful overall survival benefit in the prespecified per-protocol and sensitivity analyses, with median overall survival of 53 versus 36 months. The long-term analysis (Bridgewater et al., JCO 2022, median follow-up 106 months) confirmed a durable benefit, supporting capecitabine’s adoption as adjuvant standard of care.

Advanced or metastatic disease: chemoimmunotherapy first-line

For advanced, unresectable, or metastatic biliary tract cancer, the first-line standard has evolved from gemcitabine plus cisplatin (the ABC-02 regimen) to chemoimmunotherapy with the addition of a PD-L1 or PD-1 inhibitor. Two large phase III trials drive current practice. TOPAZ-1 (Oh et al., NEJM Evidence 2022; 3-year update in Lancet Gastroenterology & Hepatology 2024) randomized 685 patients to gemcitabine/cisplatin with or without durvalumab and demonstrated an overall survival hazard ratio of 0.80, with the 24-month survival rate nearly doubling (approximately 25% versus 10%). KEYNOTE-966 (Kelley et al., Lancet 2023) confirmed a similar benefit with pembrolizumab added to gemcitabine/cisplatin, with median overall survival of 12.7 months versus 10.9 months and a favorable toxicity profile. Both combinations are FDA- and EMA-approved and are considered category 1 first-line options. A biweekly modified TOPAZ-1 regimen (Mayo Clinic experience) offers comparable efficacy with a more favorable toxicity profile and may be preferable for older or frail patients.

Second-line and beyond

After progression on gemcitabine/cisplatin-based therapy, FOLFOX (folinic acid, 5-FU, oxaliplatin) has demonstrated a modest but reproducible survival benefit over active symptom control (ABC-06 trial) and remains the chemotherapy standard. The bigger opportunity, however, is matched precision therapy. Molecular profiling should be obtained early — ideally at diagnosis — because approximately half of CCAs harbor actionable alterations, with the highest yield in intrahepatic disease.

Targeted therapy by molecular alteration

Infigratinib’s FDA approval for FGFR2-altered CCA was withdrawn in 2024 following termination of the confirmatory first-line trial; pemigatinib and futibatinib remain available. Ongoing trials (SAFIR-ABC10, FIDES-01) are evaluating biomarker-guided maintenance and first-line use of targeted therapy.

Locoregional and supportive interventions

For unresectable intrahepatic disease, liver-directed therapies including yttrium-90 radioembolization, hepatic artery infusion pump floxuridine (particularly at experienced centers such as MSKCC), stereotactic body radiotherapy, and external-beam radiation may prolong local control and, in selected responders, enable downstaging to resection. Biliary decompression via ERCP or percutaneous transhepatic stenting is essential in the presence of obstructive jaundice before systemic therapy, both to improve hepatic function and to reduce infection risk. Cholangitis prophylaxis, fat-soluble vitamin replacement, and pancreatic enzyme assessment should accompany any patient with significant biliary obstruction.

3. Integrative Oncology Evidence Review

The role of integrative oncology in cholangiocarcinoma is supportive and complementary — layered onto, never a substitute for, guideline-based oncology care. Evidence for any single complementary modality in cholangiocarcinoma specifically is limited, but a constellation of biologically plausible therapies has accrued meaningful data in related hepatobiliary and gastrointestinal malignancies. The emphasis below is on interventions with at least preliminary human data or a strong mechanistic rationale, while flagging drug interactions relevant to gemcitabine, cisplatin, durvalumab, pembrolizumab, and the FGFR/IDH inhibitors.

Low-dose naltrexone (LDN)

LDN (typically 1.5–4.5 mg orally at bedtime) antagonizes the opioid growth factor receptor (OGFr) axis, transiently, leading to compensatory upregulation of endogenous opioid growth factor (OGF, or [Met5]-enkephalin), which in turn inhibits DNA synthesis in multiple cancer cell lines. LDN also modulates Toll-like receptor 7–9 signaling, dampens IL-6, and shifts macrophage polarization toward an M1 phenotype, with preclinical evidence of enhanced natural-killer-cell activity (Trojniak et al., Pharmaceuticals 2024; Liu et al., Int J Oncol 2016).

Direct clinical evidence in cholangiocarcinoma is limited but notable. Berkson’s published case series used intravenous alpha-lipoic acid (300–600 mg) combined with oral LDN 4.5 mg nightly in patients with metastatic pancreatic cancer, documenting long-term survival including one patient alive and well 78 months after presentation (Berkson et al., Integr Cancer Ther 2006; 2009). Schwartz et al. (Anticancer Research 2014) extended the protocol by adding hydroxycitrate and reported a prospective case series of ten heavily pretreated, chemoresistant patients, one of whom had cholangiocarcinoma. The triple metabolic regimen was well tolerated with signals of clinical benefit in this refractory setting. A 2025 case series from a tertiary pain-management center (Chwistek et al., J Pain Symptom Manage 2025) found an 80% response rate for refractory cancer pain with LDN titration to a median of 3.0 mg daily and minimal adverse events, supporting LDN’s role in symptom management in addition to any disease-modifying effect.

Alpha-lipoic acid (ALA)

Alpha-lipoic acid is a dithiol cofactor of mitochondrial pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. In tumor cells, ALA exerts paradoxical pro-oxidant effects at pharmacologic doses, stabilizes NF-κB, induces p27-dependent cell-cycle arrest, and promotes apoptosis selectively in malignant cells while preserving normal cells (Wenzel et al., Apoptosis 2005; Van de Mark et al., J Cell Physiol 2003). In hepatobiliary disease specifically, ALA was originally investigated for hepatoprotection in Amanita phalloides poisoning (Berkson, NEJM 1979) and in hepatitis C cirrhosis with the triple antioxidant protocol of ALA, silymarin, and selenium.

The most directly relevant oncology data come from the Berkson pancreatic case series (2006, 2009) and the Schwartz metabolic triple-therapy series (2014), both using intravenous ALA at 300–600 mg combined with oral LDN. Although these are case-series data and not randomized controlled trials, they are reproducible, biologically coherent, and low-toxicity. Oral ALA 300–600 mg twice daily is typical in outpatient integrative protocols; intravenous ALA requires a specialized infusion setting and screening for thiamine status to reduce risk of lactic acidosis.

Ketogenic diet and therapeutic ketosis

The biologic rationale for a ketogenic diet in cancer rests on the Warburg effect: tumor cells preferentially ferment glucose to lactate even in the presence of oxygen, while ketone bodies (beta-hydroxybutyrate and acetoacetate) are metabolized predominantly by mitochondrial oxidative phosphorylation in normal tissues. Restricting carbohydrate intake to 20–50 g per day raises ketone levels (typically ≥ 0.5 mmol/L), reduces insulin and IGF-1 signaling, and may sensitize tumors to chemotherapy and radiation (Weber et al., Mol Metab 2020).

Preclinical hepatobiliary data are positive: ketogenic interventions inhibit tumor proliferation in hepatocyte-derived liver cancer models and improve survival in animal studies. Human data remain mixed and predominantly come from feasibility trials. The VA Pittsburgh Tan-Shalaby trial (2016) in advanced cancers showed that a modified Atkins-style ketogenic diet was safe and tolerable, with preliminary signals of stable disease in a subset of patients. Cohen et al. (Nutrients 2018) reported improved body composition and quality-of-life measures in ovarian and endometrial cancer with a ketogenic regimen. A 2024 meta-analysis of randomized controlled trials (Khodabakhshi et al., Nutr Bull 2024) found consistent effects on glycemic control and body composition but insufficient evidence to conclude a direct survival benefit.

In cholangiocarcinoma specifically, prospective trial data are absent, but the rationale is strong given the Warburg phenotype and frequent co-occurring insulin resistance in this population. Clinical pearls: avoid frank ketogenic dieting in patients with active cachexia or severe sarcopenia, during biliary obstruction with fat malabsorption, or in the peri-operative window without nutrition-team supervision. A modified low-glycemic, whole-food, Mediterranean-style approach with adequate protein (1.0–1.2 g/kg/day, higher with active treatment) and intermittent ketogenic windows is generally more sustainable and equally evidence-supported.

High-dose intravenous vitamin C (pharmacologic ascorbate)

Pharmacologic doses of intravenous vitamin C (IVC) achieve millimolar plasma concentrations unattainable by oral administration, at which ascorbate acts as a pro-oxidant in tumor cells via extracellular hydrogen peroxide generation. In tumor cells, this depletes NAD+ and ATP, inhibits motility through tubulin acetylation, and suppresses epithelial-mesenchymal transition. Selectivity arises because many cancers have reduced catalase and upregulated glucose transporters (notably GLUT1), concentrating ascorbate intracellularly (Chen et al., PNAS 2005; Ma et al., Sci Transl Med 2014).

The most consequential recent data come from pancreatic cancer, a biologic neighbor of CCA. Bodeker, Cullen, and colleagues (Redox Biology 2024; NCT02905578) randomized 36 patients with stage IV pancreatic adenocarcinoma to gemcitabine and nab-paclitaxel with or without IVC 75 g three times weekly. The ascorbate arm nearly doubled median overall survival (16.0 versus 8.3 months; HR 0.46) and median progression-free survival (6.2 versus 3.9 months), with no added toxicity. Earlier, Hoffer et al. (PLOS One 2015; phase I/II in advanced cancers including biliary primaries) documented safety and pharmacokinetic feasibility of IVC at 1.5 g/kg three times weekly alongside chemotherapy, including an ampullary-adenocarcinoma case with 17 months of disease stability. No randomized CCA-specific trial exists, but given the high-risk biology and pancreatic-cancer extrapolation, IVC is among the most defensible adjunctive therapies for advanced biliary tract disease in experienced hands.

Melatonin

Melatonin is a pleiotropic indoleamine with direct antioxidant, circadian-regulatory, and oncostatic activity. In hepatobiliary cancer specifically, a 2021 systematic review (Fernández-Palanca et al., Antioxidants) synthesized 51 studies showing melatonin inhibited proliferation, angiogenesis, and invasion while promoting apoptosis and immune-response activation in both hepatocellular carcinoma and cholangiocarcinoma models. Laothong et al. (Oncol Rep 2015) specifically demonstrated melatonin-induced apoptosis in cholangiocarcinoma cell lines via mitochondrial reactive-oxygen-species pathways. A 2005 meta-analysis by Mills et al. (J Pineal Res) of ten randomized trials in solid tumors found melatonin (typically 20 mg at bedtime) reduced one-year mortality (relative risk ~0.66) and improved chemotherapy tolerability. While trial quality was mixed, the safety profile is excellent and the circadian benefits alone — improved sleep, reduced fatigue, mitigation of chemotherapy-induced insomnia — justify routine consideration at 3–20 mg at bedtime.

Vitamin D

Cholangiocytes strongly express the vitamin D receptor (VDR), and VDR expression increases during cholangiocarcinoma development, with high expression associated with better prognosis (Seubwai et al., Cancer 2007). Dietary supplementation with vitamin D3 suppressed tumor initiation and progression in a chemically induced rat ICC model, partially through downregulation of lipocalin-2 (Chiang et al., Am J Cancer Res 2014). A small pilot of high-dose intermittent calcitriol in advanced ICC demonstrated tolerability (Sookprasert et al., APJCP 2012). Beyond direct antitumor effects, vitamin D sufficiency supports bone health in a population already at risk for osteosarcopenia, which is an independent predictor of poor overall survival after BTC resection (multiple cohort studies; meta-analysis adjusted HR ~2.0 for sarcopenia). A target 25-hydroxyvitamin D level of 50–80 ng/mL with 2,000–5,000 IU/day is reasonable, with monitoring every 3–6 months.

Curcumin (bioavailable formulations)

Curcumin, the principal polyphenol of Curcuma longa, inhibits NF-κB, STAT3, and multiple cell-signaling pathways in cholangiocarcinoma cell lines, inducing apoptosis through caspase activation and mitochondrial dysfunction (Prakobwong et al., Carcinogenesis 2011; curcumol analogs, Zhang et al., Cell Death Dis 2023). In Opisthorchis-associated CCA models endemic to Thailand, curcumin showed both chemopreventive and chemotherapeutic activity (Pinlaor et al., PLOS Negl Trop Dis 2018). Oral curcumin has notoriously poor bioavailability; liposomal, phytosomal, nanoparticle, or piperine-enhanced formulations (500–2,000 mg/day) are preferred. Caution with concurrent anticoagulants and with CYP3A4-dependent drugs; wash-out of 48–72 hours around chemotherapy is conservative practice.

Mistletoe (Viscum album) extracts

European mistletoe extracts (Iscador, Helixor, Abnoba viscum) are widely used in integrative oncology in Central Europe with predominantly subcutaneous, but increasingly intravenous and intratumoral, administration. A 2010 systematic review of 26 randomized trials (Kienle & Kiene, Integrative Cancer Therapies) found quality-of-life benefits in 22 of 26 studies; a 2022 systematic review and meta-analysis on cancer-related fatigue (Pelzer et al., Support Care Cancer) confirmed mistletoe’s effect on fatigue. Intravenous mistletoe safety data in 475 patients show adverse drug reactions in 4.6% (all mild to moderate; Steele et al., eCAM 2014). CCA-specific data are limited, but an intratumoral mistletoe series in unresectable pancreatic carcinoma (Schad et al., Integr Cancer Ther 2014) reported feasibility in 39 patients. For most patients with CCA, subcutaneous mistletoe from a practitioner trained in anthroposophic medicine is a reasonable quality-of-life and immune-modulatory adjunct.

Medicinal mushrooms and other immunomodulators

Coriolus versicolor polysaccharide-K (PSK) and polysaccharopeptide (PSP) have the most robust Asian oncology data, with randomized trials in gastric, colorectal, and hepatocellular carcinoma showing overall-survival benefits when added to standard therapy. Direct CCA data are absent, but the biology — natural-killer-cell activation, dendritic-cell maturation, cytokine modulation — is relevant to a tumor with substantial immune-checkpoint responsiveness. Reishi (Ganoderma lucidum), turkey tail, and maitake extracts are frequently used at 1–3 g/day of a standardized beta-glucan preparation and are generally well tolerated.

Nutritional optimization, prehabilitation, and physical activity

Sarcopenia is present in roughly 50% of patients undergoing BTC resection and is an independent predictor of reduced overall survival, recurrence-free survival, and postoperative major complications (26-study meta-analysis, World J Surg Oncol 2024). Osteosarcopenia (concomitant sarcopenia plus osteopenia) carries an even worse prognosis (Kuwata et al., Surgery Today 2022). Practical implications: all patients with cholangiocarcinoma warrant a baseline body-composition assessment at L3 on the diagnostic CT, early protein-forward nutrition (1.2–1.5 g/kg/day with active treatment), vitamin D and calcium repletion, bile-salt therapy in cholestatic states, pancreatic enzyme replacement if there is steatorrhea, and structured resistance training during all phases of care when safe. ASCO and the Society for Integrative Oncology have endorsed graded aerobic plus resistance exercise during chemotherapy for fatigue and quality-of-life benefits.

Psychosocial, mind-body, and symptom-focused care

Acupuncture has randomized-trial support for chemotherapy-induced nausea, aromatase-inhibitor arthralgia, and cancer-related pain, with plausible benefit for gemcitabine-related nausea and paclitaxel-related neuropathy. Mindfulness-based stress reduction and yoga improve anxiety, sleep, and fatigue. Cognitive-behavioral therapy for insomnia (CBT-I), trauma-informed counseling, and peer support are all appropriate components of a whole-person plan. The Society for Integrative Oncology–ASCO joint guidelines (2022, 2023) now formally endorse acupuncture, hypnosis, massage, and music therapy for several cancer-related symptoms.

4. Integrative Oncology Checklist for Cholangiocarcinoma

Organized into domains that map to a typical initial integrative oncology consultation at Direct Integrative Care. Items marked with clinical considerations require screening laboratory values, medication review, and coordination with the treating oncologist.

Diagnostic and molecular foundation

• Comprehensive genomic profiling: tissue and/or liquid biopsy covering FGFR2, IDH1/2, HER2/ERBB2, BRAF, NTRK, RET, MSI/dMMR, BRCA1/2 — obtained at diagnosis, not after second-line failure
• Body composition: baseline L3 skeletal muscle index and psoas-muscle density from diagnostic CT; vitamin D (25-OH), prealbumin, CRP, CA 19-9, liver panel
• Microbiome and GI assessment: stool testing if chronic symptoms; pancreatic enzyme trial if steatorrhea; bile-salt repletion if cholestatic

Conventional backbone

• Surgical evaluation at a high-volume hepatobiliary center: for any potentially resectable disease, including repeat opinion if initial center deemed unresectable
• Adjuvant capecitabine: for six months post-resection (BILCAP standard)
• First-line for advanced disease: gemcitabine/cisplatin with durvalumab or pembrolizumab; consider modified biweekly schedule for frailty
• Matched targeted therapy: pursued as soon as an actionable alteration is identified
• Clinical-trial search: via ClinicalTrials.gov and the Cholangiocarcinoma Foundation registry at every decision point

Evidence-based integrative adjuncts

• Low-dose naltrexone: 1.5 mg titrated to 4.5 mg at bedtime; verify no concurrent opioids; monitor for vivid dreams
• Alpha-lipoic acid: oral 300–600 mg twice daily, or intravenous 300–600 mg one to three times weekly in qualified infusion settings; pair with thiamine
• IV vitamin C (pharmacologic ascorbate): 25–75 g per infusion, one to three times weekly, alongside chemotherapy; screen G6PD; monitor renal function and oxalate risk
• Therapeutic ketosis or low-glycemic Mediterranean framework: individualized by weight, cachexia risk, and treatment phase; avoid strict ketogenic dieting during active cachexia or biliary obstruction without nutrition-team oversight
• Melatonin: 3–20 mg at bedtime for circadian support and possible oncostatic benefit; pair with sleep hygiene
• Vitamin D3: titrate 2,000–5,000 IU/day to serum 25-OH vitamin D of 50–80 ng/mL
• Bioavailable curcumin: 500–2,000 mg/day of liposomal or phytosomal formulation; wash out 48–72 hours around chemotherapy
• Medicinal mushroom complex: 1–3 g/day standardized beta-glucan preparation (Coriolus, Reishi, Maitake)
• Mistletoe (Viscum album) therapy: with a qualified practitioner, if accessible, for quality of life and immune support

Lifestyle, resilience, and symptom care

• Structured exercise: aerobic plus resistance training, 150 minutes per week aerobic and two sessions of resistance, adapted to performance status and post-operative timeline
• Whole-foods protein-forward nutrition: 1.2–1.5 g/kg/day protein; minimize ultra-processed foods; emphasize cruciferous vegetables, berries, fatty fish, olive oil
• Mind-body practices: mindfulness-based stress reduction, yoga, breathwork; CBT-I for insomnia
• Acupuncture: for chemotherapy-induced nausea, neuropathy, and cancer-related pain
• Psychosocial support: individual counseling, support groups (e.g., the Cholangiocarcinoma Foundation peer network), caregiver support
• Spiritual and meaning-centered care: chaplaincy, meaning-centered psychotherapy for advanced disease

Interaction and safety review

• CYP450 interaction check: green tea extract, St. John’s wort, grapefruit juice, high-dose curcumin, and many antioxidants can alter chemotherapy metabolism; review quarterly
• Antioxidant timing: time any high-dose antioxidant away from chemotherapy/radiation where mechanism is pro-oxidant dependent; confirm with the treating oncologist
• Bleeding risk: review anticoagulants alongside fish oil, curcumin, ginkgo, high-dose vitamin E
• Immune-checkpoint inhibitor considerations: caution with immunostimulant mushroom blends and mistletoe in patients with active immune-related adverse events; coordinate closely with the oncology team

5. Clinical Perspective

Cholangiocarcinoma has shifted from a uniformly bleak diagnosis to a disease with real, measurable advances: chemoimmunotherapy as a new first-line standard, precision therapy for roughly half of patients with an actionable alteration, and an expanding evidence base for integrative approaches that can meaningfully extend quality of life and, in some cases, survival. The integrative oncology role is not to compete with surgery, chemoimmunotherapy, or targeted therapy but to amplify their benefit, protect the patient from their toxicities, and preserve the physiologic reserve, psychological resilience, and spiritual grounding that make long-term survivorship possible. Every CCA patient deserves both: the most rigorous evidence-based oncology available and a thoughtfully constructed integrative plan woven into it.

Selected References

1.  Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol. 2018;7(5):52.

2.  Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673.

3.  Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40(18):2048–2057.

4.  Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). NEJM Evid. 2022;1(8):EVIDoa2200015.

5.  Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694–704.

6.  Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966). Lancet. 2023;401(10391):1853–1865.

7.  Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy). Lancet Oncol. 2020;21:796–807. Final OS: JAMA Oncol. 2021;7:1669–1677.

8.  Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma (FIGHT-202). Lancet Oncol. 2020;21:671–684.

9.  Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228–239.

10.  Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5(1):83–89.

11.  Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N protocol for metastatic and non-metastatic pancreatic cancer. Integr Cancer Ther. 2009;8(4):416–422.

12.  Schwartz L, Buhler L, Icard P, et al. Metabolic treatment of cancer: intermediate results of a prospective case series. Anticancer Res. 2014;34(2):973–980.

13.  Trojniak J, Sendera A, Kieronska-Rudek A, et al. Low-dose naltrexone as an adjuvant in combined anticancer therapy. Pharmaceuticals. 2024;17(3):373.

14.  Liu WM, Scott KA, Dennis JL, et al. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses. Int J Oncol. 2016;49(2):793–802.

15.  Bodeker KL, Smith BJ, Berg DJ, et al. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024;77:103375.

16.  Hoffer LJ, Robitaille L, Zakarian R, et al. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015;10(4):e0120228.

17.  Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells. PNAS. 2005;102(38):13604–13609.

18.  Fernández-Palanca P, Méndez-Blanco C, Fondevila F, et al. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants. 2021;10(1):103.

19.  Laothong U, Hiraku Y, Oikawa S, et al. Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway. Oncol Rep. 2015;33(3):1443–1449.

20.  Seubwai W, Wongkham C, Puapairoj A, et al. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer. 2007;109(12):2497–2505.

21.  Chiang KC, Yeh CN, Hsu JT, et al. Chemopreventive and chemotherapeutic effects of dietary supplementation of vitamin D on cholangiocarcinoma. Am J Cancer Res. 2014;4(5):605–615.

22.  Prakobwong S, Gupta SC, Kim JH, et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis. 2011;32(9):1372–1380.

23.  Kienle GS, Kiene H. Influence of Viscum album L. extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142–157.

24.  Pelzer F, Loef M, Martin DD, Baumgartner S. Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis. Support Care Cancer. 2022;30(8):6405–6418.

25.  Xu Y, Tan S, Xu X, et al. Impact of imaging-diagnosed sarcopenia on outcomes in patients with biliary tract cancer after surgical resection: a systematic review and meta-analysis. World J Surg Oncol. 2024;22:240.

26.  Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in the treatment of cancer — where do we stand? Mol Metab. 2020;33:102–121.

27.  Tan-Shalaby JL, Carrick J, Edinger K, et al. Modified Atkins diet in advanced malignancies: final results of a safety and feasibility trial. Nutr Metab. 2016;13:52.

28.  Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. Int J Mol Sci. 2025;26:10755.

29.  Chwistek M, Desai T, Arenas-Cavero A, et al. Low dose naltrexone for refractory cancer pain: case series of initial safety and effectiveness. J Pain Symptom Manage. 2025 (published online).